ArticleMedicine2025
Predictive model development for invasive syndrome in type 2 diabetes mellitus patients with Klebsiella pneumoniae liver abscess: A 5-year multi-center retrospective case-control study.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to develop and validate a robust nomogram for predicting the risk of invasive Klebsiella pneumoniae liver abscess syndrome (IKPLAS) in patients with type 2 diabetes mellitus (T2DM) and K pneumoniae liver abscess. In this multicenter retrospective case-control study, clinical data from 213 patients with T2DM and K pneumoniae liver abscess, treated between January 1, 2019, and January 1, 2024, at Beijing Rehabilitation Hospital, Capital Medical University, The Sanming Integrative Medicine Hospital, and The First Affiliated Hospital of Guangzhou Medical University, were analyzed. Patients were categorized into IKPLAS (n = 25) and non-IKPLAS (n = 188) groups. Candidate variables, including fasting blood glucose, hemoglobin, blood urea nitrogen, abscess size, and Sequential Organ Failure Assessment score, were evaluated. Lasso regression and multivariate logistic regression analyses were used to identify significant predictors, which were then incorporated into a nomogram. The model's performance was assessed using receiver operating characteristic curves, calibration curves, and decision curve analysis. Multivariate logistic regression identified fasting blood glucose (odds ratio [OR] = 1.20, 95% confidence interval [CI]: 0.98-1.48, P = .006), hemoglobin (OR = 0.90, 95% CI: 0.86-0.95, P < .001), blood urea nitrogen (OR = 1.22, 95% CI: 1.03-1.43, P = .017), abscess size (OR = 0.76, 95% CI: 0.61-0.94, P = .010), and Sequential Organ Failure Assessment score (OR = 3.08, 95% CI: 2.18-4.36, P < .001) as significant predictors of IKPLAS. The nomogram demonstrated excellent discriminatory ability, with an area under the receiver operating characteristic curve of 0.966 (95% CI: 0.943-0.989) in the training set and 0.946 (95% CI: 0.902-0.991) in the validation set. Calibration curves indicated strong agreement between predicted and observed outcomes, and decision curve analysis showed that the nomogram provided substantial clinical net benefit, particularly within the risk threshold range of 0.10 to 0.40. These findings suggest that the proposed nomogram is an effective tool for predicting IKPLAS risk in patients with T2DM and K pneumoniae liver abscess, enabling early identification of high-risk patients and supporting timely clinical intervention to improve prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.